The next generation of PPAR drugs: Do we have the tools to find them?

被引：97

作者：

Shearer, Barry G. ^{[1
]}

Billin, Andrew N. ^{[1
]}

机构：

[1] Glaxo Res Dev, Res Triangle Pk, NC 27709 USA

来源：

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS | 2007年 / 1771卷 / 08期

关键词：

PPAR; safety; drug discovery; TZD;

D O I：

10.1016/j.bbalip.2007.05.005

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Agonists of PPAR alpha and PPAR gamma are currently approved for use in treating, respectively, dyslipidernia and type 2 diabetes. Agonists of PPAR beta/delta are currently in development by several pharmaceutical companies. Despite their therapeutic importance, there are dose limiting side effects associated with PPAR drug treatments, thus a new generation of safer PPAR drugs are being actively sought after. In this review we will discuss the side effects associated the PPARs, how the current drugs in clinical development were discovered and new concepts in how to screen for PPAR drugs. (c) 2007 Elsevier B.V All rights reserved.

引用

页码：1082 / 1093

页数：12

共 70 条

[1] The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes [J].

Altshuler, D ;

Hirschhorn, JN ;

Klannemark, M ;

Lindgren, CM ;

Vohl, MC ;

Nemesh, J ;

Lane, CR ;

Schaffner, SF ;

Bolk, S ;

Brewer, C ;

Tuomi, T ;

Gaudet, D ;

Hudson, TJ ;

Daly, M ;

Groop, L ;

Lander, ES .

NATURE GENETICS, 2000, 26 (01) :76-80

[2]

Baer AN, 2007, CURR OPIN RHEUMATOL, V19, P67

[3]

BALNIT BL, 2006, ENDOCR METAB IMMUNE, V6, P33

[4] PPARδ:: a dagger in the heart of the metabolic syndrome [J].

Barish, GD ;

Narkar, VA ;

Evans, RM .

JOURNAL OF CLINICAL INVESTIGATION, 2006, 116 (03) :590-597

[5] The mechanisms of action of PPARs [J].

Berger, J ;

Moller, DE .

ANNUAL REVIEW OF MEDICINE, 2002, 53 :409-435

[6] Distinct properties and advantages of a novel peroxisome proliferator-activated protein γ selective modulator [J].

Berger, JP ;

Petro, AE ;

Macnaul, KL ;

Kelly, LJ ;

Zhang, BB ;

Richards, K ;

Elbrecht, A ;

Johnson, BA ;

Zhou, GC ;

Doebber, TW ;

Biswas, C ;

Parikh, M ;

Sharma, N ;

Tanen, MR ;

Thompson, GM ;

Ventre, J ;

Adams, AD ;

Mosley, R ;

Surwit, RS ;

Moller, DE .

MOLECULAR ENDOCRINOLOGY, 2003, 17 (04) :662-676

[7] PPARs: therapeutic targets for metabolic disease [J].

Berger, JP ;

Akiyama, TE ;

Meinke, PT .

TRENDS IN PHARMACOLOGICAL SCIENCES, 2005, 26 (05) :244-251

[8] Recent findings concerning thiazolidinediones in the treatment of diabetes [J].

Boden, G ;

Zhang, M .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2006, 15 (03) :243-250

[9] Muraglitazar, a dual (α/γ) PPAR activator:: A randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes [J].

Buse, JB ;

Rubin, CJ ;

Frederich, R ;

Viraswami-Appanna, K ;

Lin, KC ;

Montoro, R ;

Shockey, G ;

Davidson, JA .

CLINICAL THERAPEUTICS, 2005, 27 (08) :1181-1195

[10]

Calkin Anna C, 2003, Curr Opin Investig Drugs, V4, P444

← 1 2 3 4 5 6 7 →